Jay S Stout has sold IMVT and made no open-market buys since Apr 2024

Jay S. Stout, PhD, MS, is a Person and serves as Chief Technology Officer at Immunovant, Inc.( In that role, he leads process development for batoclimab and IMVT-1402, CMC for clinical manufacture, supply chain, analytical sciences, and tech transfer of commercial-scale processes, supporting the company’s clinical and future manufacturing operations.(

Stout previously worked as an independent consultant from 2020 to April 2023, helping scale and validate late-stage immunology and cell and gene therapy products, and earlier led Technical Operations at Immunomedics (Gilead), where he helped advance an antibody-drug conjugate approval in oncology.( He has also held senior technical operations roles at Versartis, San Bio, Merck, Amgen, Pfizer, and BioNebraska (Restoragen), and has served for more than a decade on the Amgen Center for BioProcessing Advisory Board at the Keck Graduate Institute, including as chair from 2021 to 2023.( Stout earned a B.S. and M.S. in Chemistry from the University of Iowa and a Ph.D. in Chemistry and Biochemistry from the University of Nebraska–Lincoln.(

Written by Perplexity from public sources.